AstraZeneca Bets Big On Moderna’s Preclinical Messenger RNA Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
The struggling pharma pays $240 million upfront for an exclusive collaboration to discover, develop and commercialize mRNA drugs in the cardiovascular, metabolic, renal and oncology spaces.